All In Biotech

Drug Trial Radar · NCT04155749

Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma

Master Protocol for the Phase 1 Study of Cell Therapies for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, Including Long-term Safety Follow-up

Last checked: Nov 20, 2026Latest source record: Feb 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

40

Actual

Start

Dec 23, 2019

Primary completion

Oct 3, 2024

Study completion May 2027

Sponsor

Lead sponsor
Kite, A Gilead CompanyGilead Sciences (GILD)
Sponsor type
Industry
Collaborators
Arcellx, Inc.
First posted
Nov 7, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Master protocol for cell therapy, Phase 1 proof-of-concept studies in relapsed and refractory multiple myeloma and includes long-term safety follow-up.

Conditions

  • Relapsed and Refractory Multiple Myeloma

Interventions

  • anitocabtagene-autoleucelDrug

    Chimeric Antigen Receptor T cells

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse events (TEAEs), including DLT(s)Time frame: 24 months
  2. Establish the RP2D of the investigational agentTime frame: 24 months

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Advanced Cellular Therapeutics Facility, DCAM 0800A

    Chicago, Illinois

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Froedtert Hospital/Medical College of Wisconsin

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.